TY - JOUR T1 - Sunitinib-induced Complete Response in Metastatic Renal Cancer Expressing Neuroendocrine Markers: A New Predictive Factor? JF - Anticancer Research JO - Anticancer Res SP - 7361 LP - 7365 VL - 34 IS - 12 AU - DONATELLA GAMBINI AU - ELISA LOCATELLI AU - UMBERTO GIANELLI AU - CLAUDIA BAREGGI AU - BARBARA GALASSI AU - ROBERTO VISINTIN AU - SARA MASSIRONI AU - PAOLO G. DELL'ORTO AU - MAURIZIO TOMIROTTI Y1 - 2014/12/01 UR - http://ar.iiarjournals.org/content/34/12/7361.abstract N2 - Background: To date, no predictive factors are recognized and applied in the therapeutic choice for metastatic renal cell carcinoma. Due to significant side-effects and costs, which are relevant issues in this setting, optimization of treatments has become a priority. Case Report: We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. Since pancreatic metastases were detected by a 68Ga-DOTA-NOC positron emission tomography, it was decided to perform a histological revision of the specimens, with immunohistochemical staining for neuroendocrine markers on the primary tumor. Conclusion: On the basis of the detection of neuroendocrine markers on the primary neoplasm, together with pancreatic metastases positive on a 68Ga-DOTA-NOC positron emission tomography (PET), we hypothesize and discuss about a potential role of specific neuroendocrine markers as predictive indicators of response to sunitinib (and allegedly to other target therapies) in the treatment of this neoplasm. ER -